• Mashup Score: 0
    Webprogram Unavailable - 2 month(s) ago

    Please click HERE if you are not redirected in 5

    Tweet Tweets with this article
    • Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM) [Dec 10, 2022] @camilagdeblois et al. Abst 99 #ASH22 https://t.co/izMBdiswlP #mmsm #mmMRD https://t.co/Pqd9dhwohw

  • Mashup Score: 0
    Webprogram Unavailable - 2 month(s) ago

    Please click HERE if you are not redirected in 5

    Tweet Tweets with this article
    • Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study [Dec 10, 2022] @NoemiPuigM et al. @BerdejaJesus Abs 1859 #ASH22 https://t.co/mCCkPgMebV #mmsm #globonc https://t.co/JkTBMSg0au

  • Mashup Score: 0

    Talquetamab “demonstrated robust effic acy and manageable safety” in patients with heavily pretreated relapsed or refractory multiple myeloma, according to results from the phase I/II MonumenTAL-1 study. Ajai Chari, MD, of Mount Sinai School of Medicine, presented the data on talquetamab, a bispecific antibody targeting CD3 and GPRC5D, during the 2022 American Society of Hematology (ASH) Annual Meeting. “The MonumenTAL-1 study is really exciting,” Dr. Chari said, noting the phase I portion of the study

    Tweet Tweets with this article
    • Looking back at MounmenTAL-1? Don't miss our previous coverage of the talquetamab data presented at #ASCO2023 and #ASH22! In this video interview, @AjaiChari of @UCSF speaks about the results he presented at #ASH22. 📺https://t.co/G87ZRythZ4 #mmsm https://t.co/7Bzn4YpL1s

  • Mashup Score: 0

    Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia that was presented at ASH in New Orleans. So I think there were so many great talks. There were so many great talks and I decided I would focus on just three and really…

    Tweet Tweets with this article
    • 🚀 #ASH22 Updates in ALL Immunotherapy with Inotuzumab! Van Huynh, MD @MOASC_Office @UCIrvineHealth, shared insights at #MOASC23. 🩺 Discover remarkable breakthroughs![Video]🎥: https://t.co/BBlUqPvBAS 💊 #oncology #leukemia #medicalresearch #Immunotherapy #UCIMedSchool #CARTcell https://t.co/OSKdxJCTLI

  • Mashup Score: 0

    High-dose cytarabine-containing immunochemotherapy followed by autologous hematopoiet ic stem cell transplantation (AHSCT) “failed to show superiority over” an ibrutinib-containing treatment without AHSCT in patients with mantle cell lymphoma, according to results from the phase III TRIANGLE trial. Martin Dreyling, MD, of the LMU University Hospital Munich in Germany, and colleagues conducted the study and presented its results at the 2022 American Society of Hematology Annual Meeting. The European MCL

    Tweet Tweets with this article
    • Need a refresher on the TRIANGLE study? Check out our coverage from #ASH22: https://t.co/ol6Nrfj7OK https://t.co/YFxGbrmIA6